The EPO published a patent for CRISPR/Cas genome editing technology utilizing the Campylobacter jejuni-derived RGEN system. The application (EP4194557A1) includes IPC classifications covering recombinant DNA technology (C12N 15/63), host cells (C12N 1/21), enzymes including nucleases (C12N 9/16, C12N 9/22), and nucleic acid processes (C12N 15/10). The designated states cover 31 European jurisdictions including all EU member states, the UK, and associated territories.

Biotechnology companies and research institutions working with CRISPR genome editing technology should review this patent for freedom-to-operate considerations. Organizations developing similar genome editing applications may need to evaluate potential licensing requirements or design-around strategies to avoid infringing the protected Campylobacter jejuni CRISPR/Cas system-derived RGEN technology.